SCHEMBL417778

SCHEMBL417778

CC1=C[N]N=C1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16911325 0.69
SCHEMBL16911014 0.65
SCHEMBL16910935 0.65
SCHEMBL16911825 0.65
SCHEMBL16911837 0.64
SCHEMBL16911712 0.62
SCHEMBL5602823 0.62
SCHEMBL7463000 0.60
SCHEMBL7009257 0.52
SCHEMBL12616935 0.50

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4329755-A1 EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS Pliant Therapeutics, Inc. (US) 2024-03-06 EP claimed
EP-4328230-A2 AMINO ACID COMPOUNDS AND METHODS OF USE Pliant Therapeutics, Inc. (US) 2024-02-28 EP claimed
CN-117615760-A Extended dosage regimen for integrin inhibitors 普利安特治疗公司 2024-02-27 CN claimed
EP-3761980-B1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS INC (US) 2023-11-29 EP claimed
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS INC (US) 2023-09-21 US claimed
US-20230181546-A1 TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS PLIANT THERAPEUTICS INC (US) 2023-06-15 US claimed
CN-115989235-A Methods of treating respiratory diseases using amino acid compounds 普利安特治疗公司 2023-04-18 CN claimed
EP-4146264-A1 TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS Pliant Therapeutics, Inc. (US) 2023-03-15 EP claimed
EP-4130077-A1 SYMMETRIC RAFT AGENT FOR CONTROLLED RADICAL POLYMERIZATION OF MULTI-BLOCK COPOLYMERS FOR MONOMERS WITH DIFFERENT ACTIVITIES Clariant International Ltd (CH) 2023-02-08 EP claimed
US-20230028658-A1 EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS PLIANT THERAPEUTICS INC (US) 2023-01-26 US claimed
US-7276567-B2 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-10-02 US claimed
EP-1832586-A1 Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas Oridis Biomed Forschungs- und Entwicklungs GmbH (AT) 2007-09-12 EP claimed
US-20070155748-A1 N-sulfonyl-alpha-amino-acid derivatives SYNGENTA CROP PROTECTION, INC. 2007-07-05 US claimed
JP-2007504108-A 2007-03-01 JP claimed
EP-1660441-A2 N-SULFONYL-ALPHA-AMINO-ACID DERIVATIVES Syngenta Participations AG (CH) 2006-05-31 EP claimed
US-20050261449-A1 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENT INC. 2005-11-24 US claimed
US-20050234125-A1 Alpha-sulfonylamino-acetonitriles SYNGENTA CROP PROTECTION AG (CH) 2005-10-20 US claimed
EP-1513802-A1 ALPHA-SULFONYLAMINO-ACETONITRILES Syngenta Participations AG (CH) 2005-03-16 EP claimed
WO-2005021490-A2 N-SULFONYL-α-AMINO-ACID DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2005-03-10 WO claimed
WO-2004000797-A1 ALPHA-SULFONYLAMINO-ACETONITRILES SYNGENTA PARTICIPATIONS AG (CH) 2003-12-31 WO claimed